Alzheimer's disease therapeutic trials: Eu/us task force report on recruitment, retention, and methodology

Journal of Nutrition, Health and Aging

Volumn 16, Issue 4, 2012, Pages 339-345

  Vellas, B ^a,b   Hampel, H ^c   Rouge Bugat, M E ^b   Grundman, M ^d   Andrieu, S ^a,b   Abu Shakra, S ^e   Bateman, R ^f   Berman, R ^f   Black, R ^g   Carrillo, M ^h   Donohue, M ⁱ   Mintun, M ^j   Morris, J ^f   Petersen, R ^k   Thomas, R G ⁱ   Suhy, J ^l   Schneider, L ^m   Seely, L ⁿ   Tariot, P ^o,p   Touchon, J ^q   Weiner, M ^r   Sampaio, C ^s   Aisen, P ^t   more..

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c GOETHE UNIVERSITY   (Germany)

^d Global R and D Partners   (United States)

^e ELAN PHARMACEUTICALS   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g PFIZER INC   (United States)

^h ALZHEIMER'S ASSOCIATION   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j AVID RADIOPHARMACEUTICALS   (United States)

^k MAYO CLINIC   (United States)

^l SYNARC INC   (United States)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁿ Synarc ^*  (United States)

^o BANNER ALZHEIMER S INSTITUTE   (United States)

^p UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^q MONTPELLIER UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Alzheimer's disease; Biomarkers; Neuroimaging

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; BAPINEUZUMAB; BETA CAROTENE; CELECOXIB; DIMEBON; DONEPEZIL; ESTROGEN; MEMANTINE; NAPROXEN DERIVATIVE; SELENIUM; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SCREENING; GENE MUTATION; GINKGO BILOBA; HEART PROTECTION; HUMAN; LUMBAR PUNCTURE; METHODOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; SELF CONCEPT; TREATMENT REFUSAL;

EID: 84863211664     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0044-x     Document Type: Article

References (32)

1. Schor NF (2011) What the halted phase iii gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69: 237-239.
2. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini s, Bocchiochiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, et al (2011) the alzheimer's association external quality control program for cerebrospinal fluid biomarkers. alzheimers dement 7: 386-395.
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, et al (2007) Research criteria for the diagnosis of alzheimer's disease: revising the nincds-adrda criteria. Lancet neurol 6: 734-746. (Pubitemid 47058377)
4. Dubois B, Feldman HH, Jacova C, Cummings Jl, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, et al (2010) Revising the definition of alzheimer's disease: a new lexicon. lancet neurol 9: 1118-1127.
5. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al (2011) The diagnosis of mild cognitive impairment due to alzheimer's disease: recommendations from the national institute on aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 7: 270-279.
6. Jack CR, Jr, Albert M, Knopman DS, Mckhann GM, Sperling RA, Carrillo MC, Thies B, Phelps cH (2011) introduction to revised criteria for the diagnosis of alzheimer's disease: national institute on aging and the alzheimer's association workgroup. alzheimers dement 7: 257-262.
7. Mckhann GM, Knopman DS, Chertkow H, Hyman Bt, Jack CR, Jr, Kawas CH, Klunk We, Koroshetz WJ, Manly JJ, Mayeux R, et al (2011) The diagnosis of dementia due to alzheimer's disease: recommendations from the national institute on aging and the alzheimer's association workgroup. Alzheimers Dement 7: 263-269.
8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, et al (2011) toward defining the preclinical stages of alzheimer's disease: recommendations from the national institute on aging and the alzheimer's association workgroup. Alzheimers Dement 7: 280-292.
9. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, et al (2012) Apoe modifies the association between abeta load and cognition in cognitively normal older adults. Neurology 78: 232-240.
10. Schneider LS: Recruitment methods for united states alzheimer disease prevention trials. J Nutr Health Aging. in press (2012).
11. Sabbagh MN, Tariot PN (2009) Commentary on "a roadmap for the prevention of dementia ii. leon thal symposium 2008." a national registry to identify a cohort for alzheimer's disease prevention studies. Alzheimers Dement 5: 128-129.
12. Snitz BE, O'meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Saxton J, Lopez OL, Dunn LO, Sink KM, Dekosky ST (2009) Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. Jama 302: 2663-2670.
13. Meinert cL, Mccaffrey LD, Breitner JC (2009) Alzheimer's disease anti-inflammatory prevention trial: design, methods, and baseline results. Alzheimers dement 5: 93-104
14. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H (2006) The guidage study: methodological issues. a 5-year double-blind randomized trial of the efficacy of egb 761 for prevention of alzheimer disease in patients over 70 with a memory complaint. Neurology 67: s6-s11. (Pubitemid 44684670)
15. Heart protection study collaborative group (2002) mrc/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo controlled trial. the lancet 360: 7-22.
16. Shumaker SA, Legault C, Rapp SR, Thal l, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD, et al (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health initiative memory study: a randomized controlled trial. Jama 289: 2651-2662. (Pubitemid 37430136)
17. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR (2004) designing a large prevention trial: statistical issues. Stat Med 23: 285-296. (Pubitemid 38100641)
18. Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen Ik, Du P, et al (2011) Iagg workshop: health promotion program on prevention of late onset dementia. J nutr Health aging 15: 562-575.
19. Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A (2008) dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 30: 35-66.
20. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig lS, Doody R, Van Dyck CH, et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease. neurology 73: 2061-2070.
21. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, et al (2010) Biomarkers for alzheimer's disease: academic, industry and regulatory perspectives. nat rev drug discov 9: 560-574.
22. Van Rossum IA, Vos S, Handels R, Visser PJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to alzheimer-type dementia: implications for trial design. J Alzheimers Dis 20: 881-891.
23. Prvulovic D, Hampel H (2011) Ethical considerations of biomarker use in neurodegenerative diseases-a case study of alzheimer's disease. Prog Neurobiol 95: 517-519.
24. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in alzheimer disease. Nat Rev Neurol 6: 131-144.
25. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H (2011) Neuroimaging markers for the prediction and early diagnosis of alzheimer's disease dementia. Trends Neurosci 34: 430-442.
26. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, et al (2011) Biomarkers for alzheimer's disease therapeutic trials. Prog Neurobiol 95: 579-593.
27. Sperling RA, Jack CR, Jr., Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the alzheimer's association research roundtable Workgroup. Alzheimers dement 7: 367-385.
28. Donohue MC, Aisen P (2012) Profile models versus slope models for assessing longitudinal change in alzheimer's disease clinical trials. J nutr Health aging. In press.
29. European medicines agency cHmp (2010) guidelines on missing data in confirmatory clinical trials. london, united kingdom.
30. National research council panel on Handling missing data in clinical trials (2010) the prevention and treatment of missing data in clinical trials. National academies press, Washington.
31. Schneider IS, Insel PS, Weiner MW (2011) Treatment with cholinesterase inhibitors and memantine of patients in the alzheimer's disease neuroimaging initiative. Arch neurol 68: 58-66.
32. Hampel H, Prvulovic D (2012) Are biomarkers harmful to recruitment and retention in alzheimer's disease clinical trials? an international perspective. J nutr Health aging. in press.